Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at wallstreetmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. WallStreetMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent SGEN Stock Price: $177.73
Summary: Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries. Seagen has an agreement with Takeda Pharmaceutical Company Ltd. for the further development and commercialization of Adcetris. Seagen retains all rights to sell Adcetris in the U.S. and Canada, while Takeda has commercial rights to the drug in the rest of the world. The FDA granted approvals to Seagen's several drugs named Padcev, for treating advanced/metastatic urothelial cancer; Tukysa and Tivdak for treating adult patients with locally advanced/metastatic HER2-positive breast cancer and for the treatment of recurrent/metastatic cervical cancer in adult patients respectively. The company also has license agreements with partners like Merck, Roche, GlaxoSmithKline, Astellas, AbbVie, Bristol-Myers and Genmab.
Etzer Darout analyst at BMO Capital reiterates coverage on Seagen (SGEN) stock in the energy sector with a Hold rating and has set SGEN's stock price target at $ 169.
TipRanks.com reports that Seagen currently has 11 analysts offering 12-month price targets on SGEN and the consensus is a Moderate Buy rating with an average stock price target of $170.20. The most recent SGEN stock price we have is $177.73 and we are not making any SGEN forecasts at this time.
In addition, TradingView issued a Buy rating for SGEN over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on SGEN. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SGEN, please click here >>
Chimerix, CMRX
Recent CMRX Stock Price: $2.1
Summary: Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.
Edward White analyst at H.C. Wainwright reiterates coverage on Chimerix (CMRX) stock in the energy sector with a Buy rating and has set CMRX's stock price target at $ 11.
TipRanks.com reports that Chimerix currently has 3 analysts offering 12-month price targets on CMRX and the consensus is a Strong Buy rating with an average stock price target of $8.00. The most recent CMRX stock price we have is $2.1 and we are not making any CMRX forecasts at this time.
In addition, TradingView issued a Neutral rating for CMRX over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on CMRX. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CMRX, please click here >>
Precision BioSciences, DTIL
Recent DTIL Stock Price: $1.77
Summary: Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
Patrick Trucchio analyst at H.C. Wainwright reiterates coverage on Precision BioSciences (DTIL) stock in the energy sector with a Buy rating and has set DTIL's stock price target at $ 20.
TipRanks.com reports that Precision BioSciences currently has 6 analysts offering 12-month price targets on DTIL and the consensus is a Strong Buy rating with an average stock price target of $11.20. The most recent DTIL stock price we have is $1.77 and we are not making any DTIL forecasts at this time.
In addition, TradingView issued a Buy rating for DTIL over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on DTIL. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DTIL, please click here >>
The editors at wallstreetmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
WallStreetMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetMovers.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================